Cargando…

The clinical experience of macitentan in pulmonary hypertension in Indian cohort: 12-month follow-up

BACKGROUND: The effectiveness and safety of macitentan, an endothelin-receptor antagonist (ERA) in the treatment of pulmonary arterial hypertension (PAH), has been demonstrated in numerous randomized clinical trials including SERAPHIN, focused on the reduction of morbidity and mortality. OBJECTIVES:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jariwala, Pankaj, Maturu, Venkata Nagarjuna, Jadhav, Kartik Pandurang, Punjani, Arshad, Boorugu, Harikishan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8926235/ https://www.ncbi.nlm.nih.gov/pubmed/34975047 http://dx.doi.org/10.4103/lungindia.lungindia_671_20

Ejemplares similares

ADDition of DAPAgliflozin, Sodium-Glucose Cotransporter-2 Inhibitor to Angiotensin Receptor Blocker-Neprilysin Inhibitors Non-Responders in Patient with Refractory Heart Failure with Reduced Ejection Fraction (ADD DAPA trial)
por: Jariwala, Pankaj, et al.
Publicado: (2021)

A clinical experience of Indian patients with heart failure with reduced left ventricular ejection fraction using an angiotensin receptor-neprilysin inhibitor [ARNI] on an outpatient basis
por: Jariwala, Pankaj, et al.
Publicado: (2021)

Congenital isolated unilateral hypoplasia of the left pulmonary artery: A rare incidental anomaly in an elderly female
por: Jariwala, Pankaj, et al.
Publicado: (2021)

Macitentan for the treatment of pulmonary arterial hypertension
por: Kholdani, Cyrus A, et al.
Publicado: (2014)

Macitentan in pulmonary arterial hypertension: The SERAPHIN trial
por: Said, Karim
Publicado: (2014)

Macitentan in the treatment of pulmonary hypertension in Gaucher’s disease
por: Taylan, Gökay, et al.
Publicado: (2020)

Endovascular management of the post-traumatic common carotid artery pseudoaneurysms
por: Jariwala, Pankaj, et al.
Publicado: (2021)

Left ventricular thrombus with normal systolic function secondary to the novel prothrombotic association of acute on chronic calcific pancreatitis and COVID-19
por: Jariwala, Pankaj V., et al.
Publicado: (2021)

Itraconazole in chronic pulmonary aspergillosis: In whom, for how long, and at what dose?
por: Maturu, Venkata Nagarjuna, et al.
Publicado: (2015)

Macitentan: An important addition to the treatment of pulmonary arterial hypertension
por: Khadka, Anjan, et al.
Publicado: (2015)

A fatal association of COVID-19 and acute complicated Type-B aortic dissection: Interventional management in a difficult situation
por: Jariwala, Pankaj, et al.
Publicado: (2021)

‘Ivabradin’ versus ‘Carvedilol’ in the management of Post-COVID-19 palpitation with sinus tachycardia
por: Jadhav, Kartik, et al.
Publicado: (2020)

Dual left anterior descending artery: Case series based on novel classification and its therapeutic implications
por: Jariwala, Pankaj, et al.
Publicado: (2022)

Benefits from the Early Initiation of Macitentan for Pulmonary Arterial Hypertension
por: Jung, Hae Ok
Publicado: (2018)

Safety and tolerability of macitentan in the management of pulmonary arterial hypertension: an update
por: Wong, Alexandra K, et al.
Publicado: (2019)

Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension
por: Sitbon, Olivier, et al.
Publicado: (2020)

Efficacy and safety of macitentan for pulmonary hypertension: A meta‐analysis
por: Du, Dan, et al.
Publicado: (2023)

The prevalence of risk factors and pattern of obstructive coronary artery disease in young Indians (< 45 years) undergoing percutaneous coronary intervention: A gender-based multi-center study
por: Jariwala, Pankaj, et al.
Publicado: (2022)

Safety, efficacy, and clinical utility of macitentan in the treatment of pulmonary arterial hypertension
por: Monaco, Thomas J, et al.
Publicado: (2016)

Cost-utility analysis of Macitentan Vs. Bosentan in pulmonary atrial hypertension
por: Nosrati, Marzieh, et al.
Publicado: (2020)

Safety of macitentan in sarcoidosis-associated pulmonary hypertension: a case-series
por: Mathijssen, H., et al.
Publicado: (2020)

Multiple biventricular thrombi in a patient with alcoholic cardiomyopathy and COVID-19: A tragic association in a deadly pandemic
por: Jariwala, Pankaj, et al.
Publicado: (2022)

Macitentan treatment retards the progression of established pulmonary arterial hypertension in an animal model()
por: Temple, I.P., et al.
Publicado: (2014)

Macitentan in Pulmonary Arterial Hypertension: A Focus on Combination Therapy in the SERAPHIN Trial
por: Jansa, Pavel, et al.
Publicado: (2017)

Triple oral combination therapy with macitentan, riociguat, and selexipag for pulmonary arterial hypertension
por: Momoi, Mizuki, et al.
Publicado: (2021)

Inflammatory myofibroblastic tumor of the lung in pregnancy mimicking carcinoid tumor
por: Maturu, Venkata Nagarjuna, et al.
Publicado: (2016)

Idiopathic pleuroparenchymal fibroelastosis presenting as bilateral spontaneous pneumothorax: A case report
por: Maturu, Venkata Nagarjuna, et al.
Publicado: (2019)

Pulmonary arterial hypertension outcomes upon endothelin-1 receptor antagonist switch to macitentan
por: Tynan, Timothy, et al.
Publicado: (2019)

Clinical and hemodynamic benefit of macitentan and riociguat upfront combination in patients with pulmonary arterial hypertension
por: Sulica, Roxana, et al.
Publicado: (2019)

Hemodynamic and Histopathologic Benefits of Early Treatment with Macitentan in a Rat Model of Pulmonary Arterial Hypertension
por: Kim, Kyung-Hee, et al.
Publicado: (2018)

Treatment of pulmonary arterial hypertension with the dual endothelin receptor antagonist macitentan: clinical evidence and experience
por: Belge, Catharina, et al.
Publicado: (2019)

Effects of macitentan and tadalafil monotherapy or their combination on the right ventricle and plasma metabolites in pulmonary hypertensive rats
por: Mamazhakypov, Argen, et al.
Publicado: (2020)

Prospective clinical assessment of patients with pulmonary arterial hypertension switched from bosentan to macitentan (POTENT)
por: Aldalaan, Abdullah M., et al.
Publicado: (2022)

Randomized, controlled clinical trial to evaluate efficacy of sticky bone and concentrated growth factor in the management of intrabony defects: 12 months follow-up study
por: Ghoderao, Dhanashree, et al.
Publicado: (2022)

Paraoxonase 1 (PON1) Polymorphisms, Haplotypes and Activity in Predicting CAD Risk in North-West Indian Punjabis
por: Gupta, Nidhi, et al.
Publicado: (2011)

Macitentan treatment of portopulmonary hypertension with hepatopulmonary syndrome: a case report and literature review
por: Li, Niuniu, et al.
Publicado: (2023)

Comparison of Macitentan and Bosentan on Right Ventricular Remodeling in a Rat Model of Non-vasoreactive Pulmonary Hypertension
por: Iglarz, Marc, et al.
Publicado: (2015)

The Transition From Ambrisentan to Macitentan in Patients With Pulmonary Arterial Hypertension: A Real-word Prospective Study
por: Chen, Yusi, et al.
Publicado: (2022)

Exploring the failing right ventricle in pulmonary hypertension by cardiac magnetic resonance: An in vivo study utilizing Macitentan
por: Murphy, Gerard, et al.
Publicado: (2022)

Benefits of Macitentan in Patients with Pulmonary Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Qin, Jinlv, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_mre3306i90lrji7po3vdjqfb16